What does this research mean for the field?

Specific lncRNA-stemness-immune regulatory triplets, particularly the ATAD5/PRR11-AS1/SKP2 triplet, serve as robust prognostic biomarkers across multiple cancers and accurately predict patient responses to immune checkpoint inhibitors. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to identify and characterize the interactions between long noncoding RNAs, stemness signature genes, and tumor immunity in cancer.

June 6, 2026Briefings in BioinformaticsOpen Access

Identification and characterization of lncRNA-stemness-immune regulatory patterns

View Full Paper

Ask AI

Bookmark

Authors

ZQZhipeng QianNortheast Forestry University JYJiaqi YinNortheast Forestry University CZC L ZhangHebei Agricultural University

Discussion

Member takes

Implication

Randomized trial identifies lncRNA-stemness-immune interactions predicting immunotherapy outcomes across cancers, suggesting novel biomarkers.

Key Points

This study aims to identify and characterize the interactions between long noncoding RNAs, stemness signature genes, and tumor immunity in cancer.
Developed a network-based modeling framework that includes Bayesian network inference.
Analyzed core regulatory triplets consisting of lncRNA, SSG, and immune gene.
Validated predictive potential using four machine learning algorithms across three immunotherapy cohorts.
The ATAD5/PRR11-AS1/SKP2 triplet shows a strong correlation with immune cell infiltration and favorable prognostic potential across multiple cancers.
Integrating STEM-LncCRTs with tumor mutation burden enhances predictive accuracy for 1-, 3-, and 5-year overall survival rates.
The approach outperforms individual gene markers in predicting responses to immune checkpoint inhibitors.

Cite This Study

Qian et al. (2026) studied this question.

synapsesocial.com/papers/6a23baa771a5da9775e7647d https://doi.org/10.1093/bib/bbag287

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial identifies lncRNA-stemness-immune interactions predicting immunotherapy outcomes across cancers, suggesting novel biomarkers.

Identification and characterization of lncRNA-stemness-immune regulatory patterns

Discussion

Member takes

Implication

Key Points

Cite This Study

Identification and characterization of lncRNA-stemness-immune regulatory patterns

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider